DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS In a small study of the PD-1 blocker dostarlimab, 100% of patients with locally advanced mismatch repair–deficient Stage II or III rectal adenocarcinoma experienced remission. The study participants were treated with dostarlimab monotherapy infused every three weeks for six months. The original intent was to follow dostarlimab with chemotherapy, radiation and surgery, but that turned out to be unnecessary.
Read the study summary here.
Peer-influenced content. Sources you trust. No registration required. This is HCN.